Ketoconazole
Ketoconazole (Nizoral)
Well-tolerated adjunct with antifungal, anti-inflammatory, and potential anti-androgenic properties.
How Ketoconazole works — and how well we know it
Antifungal (azole) with secondary anti-inflammatory and potential anti-androgenic properties. Reduces Malassezia-driven perifollicular inflammation, competitively binds the androgen receptor, and inhibits cytochrome P450-dependent steroidogenic enzymes.
topical
2% ketoconazole shampoo applied to scalp 2-4 times per week, left on for 3-5 minutes before rinsing. OTC 1% shampoo can be used similarly but has less evidence for hair benefits.
FDA-approved as antifungal shampoo. Off-label for AGA.
Adjunct to finasteride/minoxidil, especially with dandruff.
Evidence distribution across 9 claims
Why the grade is B. RCT evidence for 2% shampoo; systematic reviews support adjunctive use.
What the trials actually showed
Scalp condition improvements (reduced flaking, sebum, inflammation) begin within 2-4 weeks. Reduced hair shedding may be noticeable by 1-2 months. Measurable improvements in hair diameter and anagen percentage emerge by 4-6 months (Pierard-Franchimont 2002 measured at 6 months; El-Garf 2019 found significant improvement at month 6 for the ketoconazole group). This is slower onset than minoxidil, which showed significance at month 4 in the El-Garf trial.
Not precisely defined. The Pierard-Franchimont 1998 study ran for 21 months and showed continued benefit, suggesting effects may continue to accrue beyond 6 months. Most studies measuring at 6 months show ongoing improvement at the final timepoint, so peak effect likely occurs at 12-18 months of consistent use, similar to other hair loss treatments.
Yes — must continue indefinitely
Hair benefits are expected to gradually reverse upon discontinuation, as the underlying AGA process resumes. The Inui & Itami 2007 case series documented relapse in one patient after stopping treatment. The anti-inflammatory/antifungal benefits (reduced dandruff, sebum control) will revert within weeks of stopping. Hair parameter improvements likely reverse over 3-6 months, though formal discontinuation studies have not been conducted.
Side effects, contraindications, and special populations
| Adverse event | Rate | Placebo | Notes |
|---|---|---|---|
| Scalp irritation or itching | <1% (from 11 double-blind trials, n=264) | — | Mild and transient in the vast majority of cases. More likely with frequent use (>4x/week) or prolonged contact time. Resolves with discontinuation or reduced frequency. In the El-Garf 2019 RCT, only 10% of women using 2% ketoconazole microemulsion (a leave-on formulation) reported any side effects, vs 55% with minoxidil. |
| Scalp dryness | ~1-3% (from open-label safety trials and post-marketing reports) | — | The shampoo vehicle can be drying, particularly with frequent use. More common in individuals with naturally dry scalp or those using other drying hair products. Can be mitigated by using a conditioner after treatment and limiting use to 2-3x/week. |
| Abnormal hair texture | Rare (1/41 in open-label safety trial; also in post-marketing reports) | — | Reported in one patient in the open-label safety trial (6-month, 4-10x weekly shampooing). Hair may feel coarser or more brittle during treatment. Post-marketing reports include hair discoloration (mainly in chemically treated or gray hair) and texture changes. |
| Scalp pustules | Rare (1/41 in open-label safety trial) | — | Single occurrence in the extended-use open-label trial. Causality not definitively established. If pustules develop, discontinue and evaluate for folliculitis or contact reaction. |
| Contact dermatitis | Rare (0.01-0.1% from post-marketing surveillance) | — | Allergic contact dermatitis to ketoconazole itself is rare. May be more related to vehicle ingredients (surfactants, preservatives) than the active ingredient. Presents as erythema, scaling, and pruritus beyond expected treatment effects. Requires discontinuation. |
| Hair discoloration | Rare (post-marketing reports only, not seen in clinical trials) | — | Primarily reported in patients with chemically treated, permed, or gray hair. The reddish-orange color of the shampoo may temporarily stain light or damaged hair. Generally reversible upon discontinuation. |
| Oiliness or dryness of hair and scalp | Uncommon (post-marketing reports) | — | Ketoconazole reduces sebum production, which is generally beneficial for AGA patients but may result in perceived dryness in some individuals. Paradoxical oiliness has been rarely reported, possibly due to rebound sebum production. |
- Angioedema / severe hypersensitivity (Extremely rare (post-marketing reports only, not observed in clinical trials)) — Isolated post-marketing reports of angioedema and urticaria exist. These are idiosyncratic hypersensitivity reactions, not dose-dependent. Discontinue immediately and seek medical attention if facial/lip swelling or difficulty breathing occurs.
- Paradoxical alopecia (increased hair loss) (<1% (from FDA label: 'increase in normal hair loss' in <1% of 264 patients)) — Rare reports of increased hair shedding during use. May represent initial telogen effluvium from scalp adjustment, irritant-driven shedding, or coincidental AGA progression. Generally transient. If persistent beyond 2-3 months, discontinue and reassess.
- Known hypersensitivity to ketoconazole or any excipient in the formulation (Absolute) — Per FDA label. Patients with documented allergy to ketoconazole or other imidazole antifungals should not use ketoconazole shampoo.
- Open wounds or severely inflamed/broken scalp skin (Relative) — While not an absolute contraindication, applying ketoconazole shampoo to broken or acutely inflamed skin may increase irritation and theoretical systemic absorption. Allow acute scalp conditions to resolve before initiating ketoconazole shampoo treatment.
- None established for topical/shampoo formulations (N/A) — The FDA label for ketoconazole 2% shampoo lists no drug interactions. Ketoconazole is not detected in plasma after chronic shampooing, so the potent CYP3A4 inhibition that makes oral ketoconazole dangerous (QT prolongation with cisapride, terfenadine; increased levels of statins, benzodiazepines, cyclosporine, etc.) does not apply to topical use.
- Oral ketoconazole (systemic) (Note -- NOT applicable to shampoo) — Oral ketoconazole is a potent CYP3A4 inhibitor with dangerous drug interactions (FDA black box). This is irrelevant for shampoo use due to negligible systemic absorption, but patients and providers should be aware of the distinction. The shampoo and oral tablet have completely different risk profiles.
FDA Pregnancy Category C (topical). Animal reproduction studies with oral ketoconazole showed adverse effects (syndactyly, oligodactyly in rats at 80 mg/kg/day -- 10x the maximum recommended human oral dose). No adequate studies in pregnant women. However, ketoconazole is not detected in plasma after chronic shampooing, suggesting negligible fetal exposure from shampoo use. Expert opinion considers topical ketoconazole likely safe in pregnancy when used in limited areas for brief periods (Murase 2014), but should be used only if the potential benefit justifies the potential risk. Not recommended specifically for hair loss during pregnancy.
Ketoconazole shampoo is considered safe for women. The El-Garf 2019 RCT specifically studied women with FPHL and found only 10% reported side effects (vs 55% with minoxidil). Ketoconazole does not cause the hypertrichosis (unwanted facial/body hair growth) that is a common minoxidil side effect in women, making it a potentially better-tolerated adjunctive option for female patients.
Safety and effectiveness in children have not been established per FDA label. The 2% shampoo is generally not recommended for children under 12 years without physician guidance. Post-market data suggests it has been safely used in children as young as 3 years for seborrheic dermatitis, but formal pediatric studies for hair loss indications do not exist. Hair loss in children typically requires specialized evaluation rather than empiric ketoconazole use.
No specific age-related concerns identified. Ketoconazole shampoo can be used in elderly patients for both seborrheic dermatitis and as adjunctive AGA therapy. No dose adjustment needed. The lack of systemic absorption makes it safer than many other medications in elderly patients on multiple drugs.
No adequate studies in nursing women. However, since ketoconazole is not detected in plasma after chronic shampooing, exposure through breast milk from shampoo use is expected to be negligible. Exercise caution; the FDA label recommends consideration of risk vs benefit.
Every claim, traced back to its source
We took every major claim made about Ketoconazole and matched it to the specific experimental model behind it. Click a claim to see the model, the finding, and our assessment of how much weight it deserves.
9 claims · evidence-by-evidence breakdown
1RCTWeight: HighKetoconazole shampoo increases hair density and anagen percentage comparably to 2% minoxidil2% ketoconazole shampoo used 2-4x/week for 21 months produced improvements in hair density, follicle size, and anagen percentage 'almost similar' to 2% topical minoxidil in men with grade III vertex A
Human controlled trial
2% ketoconazole shampoo used 2-4x/week for 21 months produced improvements in hair density, follicle size, and anagen percentage 'almost similar' to 2% topical minoxidil in men with grade III vertex AGA (n=39).
2% ketoconazole shampoo used 2-4x/week for 21 months produced improvements in hair density, follicle size, and anagen percentage 'almost similar' to 2% topical minoxidil in men with grade III vertex AGA (n=39).
- Pierard-Franchimont C, De Doncker P, Cauwenbergh G, Pierard GE (1998). Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology PMID 9669136
2In VitroWeight: LowKetoconazole competitively binds the human androgen receptorKetoconazole achieved 50% displacement of radiolabeled androgen from the AR at 6.4 x 10^-5 M in cultured human skin fibroblasts. Among imidazole antifungals, only ketoconazole showed this AR interacti
In vitro
Ketoconazole achieved 50% displacement of radiolabeled androgen from the AR at 6.4 x 10^-5 M in cultured human skin fibroblasts. Among imidazole antifungals, only ketoconazole showed this AR interaction. Inui & Itami (2007) proposed this local anti-androgenic activity explains part of its AGA benefit.
Ketoconazole achieved 50% displacement of radiolabeled androgen from the AR at 6.4 x 10^-5 M in cultured human skin fibroblasts. Among imidazole antifungals, only ketoconazole showed this AR interaction. Inui & Itami (2007) proposed this local anti-androgenic activity explains part of its AGA benefit.
- Eil C (1992). Ketoconazole binds to the human androgen receptor. Hormone and Metabolic Research PMID 1526623
- Inui S, Itami S (2007). Reversal of androgenetic alopecia by topical ketoconazole: relevance of anti-androgenic activity. Journal of Dermatological Science PMID 16997533
3RCTWeight: Low-ModerateKetoconazole inhibits steroidogenesis via cytochrome P450 enzyme blockadeKetoconazole inhibits multiple CYP450-dependent steroidogenic enzymes (C17-20 lyase, cholesterol side-chain cleavage, 17-alpha-hydroxylase, aromatase). However, 5-alpha reductase is NOT inhibited. The
In vitro / In vivo (oral dosing)
Ketoconazole inhibits multiple CYP450-dependent steroidogenic enzymes (C17-20 lyase, cholesterol side-chain cleavage, 17-alpha-hydroxylase, aromatase). However, 5-alpha reductase is NOT inhibited. These effects are well-documented at oral/systemic doses but uncertain for topical shampoo application.
Ketoconazole inhibits multiple CYP450-dependent steroidogenic enzymes (C17-20 lyase, cholesterol side-chain cleavage, 17-alpha-hydroxylase, aromatase). However, 5-alpha reductase is NOT inhibited. These effects are well-documented at oral/systemic doses but uncertain for topical shampoo application.
- Pont A, Williams PL, Azhar S, et al. (1982). Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. Journal of Clinical Investigation PMID 6304148
4In VivoWeight: ModerateTopical ketoconazole stimulates hair regrowth in mouse models2% ketoconazole solution applied daily for 3 weeks to C3H/HeN mice produced significantly greater hair regrowth vs vehicle (ratio 0.61, p=0.006). Aldhalimi et al. (2014) confirmed this and found minox
In vivo animal
2% ketoconazole solution applied daily for 3 weeks to C3H/HeN mice produced significantly greater hair regrowth vs vehicle (ratio 0.61, p=0.006). Aldhalimi et al. (2014) confirmed this and found minoxidil was more effective than ketoconazole in mice.
2% ketoconazole solution applied daily for 3 weeks to C3H/HeN mice produced significantly greater hair regrowth vs vehicle (ratio 0.61, p=0.006). Aldhalimi et al. (2014) confirmed this and found minoxidil was more effective than ketoconazole in mice.
- Jiang J, Tsuboi R, Kojima Y, Ogawa H (2005). Topical application of ketoconazole stimulates hair growth in C3H/HeN mice. Journal of Dermatology PMID 15863844
- Aldhalimi MA, Hadi NR, Ghafil FA (2014). Promotive effect of topical ketoconazole, minoxidil, and minoxidil with tretinoin on hair growth in male mice. ISRN Pharmacology PMID 24734193
5Open-LabelWeight: HighKetoconazole increases hair shaft diameter and reduces shedding in men with AGA-related telogen effluviumIn 150 men with AGA-related telogen effluvium and dandruff, 1% ketoconazole shampoo (2-3x/week, 6 months) increased hair shaft diameter by 5.4%, anagen percentage by 4.9%, and reduced hair loss severi
Human randomized trial (open-label)
In 150 men with AGA-related telogen effluvium and dandruff, 1% ketoconazole shampoo (2-3x/week, 6 months) increased hair shaft diameter by 5.4%, anagen percentage by 4.9%, and reduced hair loss severity by 17.3%. Effects were comparable to piroctone olamine.
In 150 men with AGA-related telogen effluvium and dandruff, 1% ketoconazole shampoo (2-3x/week, 6 months) increased hair shaft diameter by 5.4%, anagen percentage by 4.9%, and reduced hair loss severity by 17.3%. Effects were comparable to piroctone olamine.
- Pierard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Pierard GE (2002). Nudging hair shedding by antidandruff shampoos: a comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. International Journal of Cosmetic Science PMID 18498517
6RCTWeight: HighestTopical ketoconazole is effective for female pattern hair loss with fewer side effects than minoxidilIn an RCT of 40 women with FPHL, 2% topical ketoconazole microemulsion achieved significant hair growth by month 6 (delayed vs minoxidil at month 4). Only 10% of ketoconazole patients reported side ef
Human RCT
In an RCT of 40 women with FPHL, 2% topical ketoconazole microemulsion achieved significant hair growth by month 6 (delayed vs minoxidil at month 4). Only 10% of ketoconazole patients reported side effects. Patient satisfaction was similar between groups.
In an RCT of 40 women with FPHL, 2% topical ketoconazole microemulsion achieved significant hair growth by month 6 (delayed vs minoxidil at month 4). Only 10% of ketoconazole patients reported side effects. Patient satisfaction was similar between groups.
- El-Garf A, Mohie M, Salah E (2019). Trichogenic effect of topical ketoconazole versus minoxidil 2% in female pattern hair loss: a clinical and trichoscopic evaluation. Biomedical Dermatology
7Open-LabelWeight: HighCombination therapy with finasteride and ketoconazole outperforms minoxidil aloneIn 100 men with Hamilton grade II-IV AGA treated for 1 year, finasteride + ketoconazole produced the second-best results (after finasteride + minoxidil). Both finasteride-containing groups significant
Human open-label randomized trial
In 100 men with Hamilton grade II-IV AGA treated for 1 year, finasteride + ketoconazole produced the second-best results (after finasteride + minoxidil). Both finasteride-containing groups significantly outperformed minoxidil alone (p<0.05). No significant side effects reported.
In 100 men with Hamilton grade II-IV AGA treated for 1 year, finasteride + ketoconazole produced the second-best results (after finasteride + minoxidil). Both finasteride-containing groups significantly outperformed minoxidil alone (p<0.05). No significant side effects reported.
- Khandpur S, Suman M, Reddy BS (2002). Comparative efficacy of various treatment regimens for androgenetic alopecia in men. Journal of Dermatology PMID 12227482
8RCTWeight: Highest (for antifungal efficacy); High (for indirect hair benefit)Ketoconazole reduces Malassezia-driven scalp inflammation, indirectly supporting hair follicle healthKetoconazole reliably reduces Malassezia colonization, perifollicular inflammation, and associated hair shedding. The Fields et al. (2020) systematic review concluded it is a 'promising adjunctive or
Systematic review / Multiple RCTs
Ketoconazole reliably reduces Malassezia colonization, perifollicular inflammation, and associated hair shedding. The Fields et al. (2020) systematic review concluded it is a 'promising adjunctive or alternative therapy' for AGA. Gupta et al. (2025) confirmed clinical superiority over other antidandruff agents and highlighted its broader hair care applications beyond seborrheic dermatitis.
Ketoconazole reliably reduces Malassezia colonization, perifollicular inflammation, and associated hair shedding. The Fields et al. (2020) systematic review concluded it is a 'promising adjunctive or alternative therapy' for AGA. Gupta et al. (2025) confirmed clinical superiority over other antidandruff agents and highlighted its broader hair care applications beyond seborrheic dermatitis.
- Fields JR, Vonu PM, Monir RL, Schoch JJ (2020). Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatologic Therapy PMID 31858672
- Gupta AK, et al. (2025). Role of topical ketoconazole in therapeutic hair care beyond seborrhoeic dermatitis and dandruff. JEADV Clinical Practice
9RCTWeight: HighestTopical ketoconazole shampoo has a favorable safety profile with minimal systemic absorptionIn 264 patients, irritation and hair loss each occurred in <1% with 2% ketoconazole shampoo. Contact dermatitis is rare (0.01-0.1%). Oral ketoconazole carries serious hepatotoxicity risk (FDA black bo
FDA label data / Clinical trials / Post-marketing surveillance
In 264 patients, irritation and hair loss each occurred in <1% with 2% ketoconazole shampoo. Contact dermatitis is rare (0.01-0.1%). Oral ketoconazole carries serious hepatotoxicity risk (FDA black box warning, 2013), but topical formulations are not associated with liver injury, adrenal suppression, or systemic anti-androgenic side effects.
In 264 patients, irritation and hair loss each occurred in <1% with 2% ketoconazole shampoo. Contact dermatitis is rare (0.01-0.1%). Oral ketoconazole carries serious hepatotoxicity risk (FDA black box warning, 2013), but topical formulations are not associated with liver injury, adrenal suppression, or systemic anti-androgenic side effects.
- FDA (2013). FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury. FDA Drug Safety Communication
What's still missing from the science
- Large RCT of ketoconazole shampoo monotherapy vs minoxidil 5%
- Long-term data beyond 21 months
- Dose-response for leave-on vs rinse-off
Our verdict on Ketoconazole
The shampoo we carry
We don't carry ketoconazole shampoo directly. Follicool uses the same scalp-microbiome rationale with a botanical anti-DHT blend instead.
From the Anagen blog
Long-form analysis and primary-source breakdowns that go beyond the summary above.
Related treatments
How does Ketoconazole stack up against its closest peers?
Most potent 5-alpha reductase inhibitor with RCT evidence of superiority over finasteride.
Read the breakdown →Strong prostaglandin biology and one small positive RCT for scalp, but validated only for eyelash growth (via bimatoprost/Latisse)
Read the breakdown →Compelling PGD2-based rationale and consistently positive clinical signals with cetirizine, but no large definitive trial — best used as an adjunct to proven treatments
Read the breakdown →